Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Finished Goods (2023 - 2025)

Historic Finished Goods for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to $7.3 million.

  • Krystal Biotech's Finished Goods rose 12657.32% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 12657.32%. This contributed to the annual value of $2.1 million for FY2024, which is 23907.5% up from last year.
  • Per Krystal Biotech's latest filing, its Finished Goods stood at $7.3 million for Q3 2025, which was up 12657.32% from $1.7 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Finished Goods high stood at $7.3 million for Q3 2025, and its period low was $161000.0 during Q1 2024.
  • Over the past 3 years, Krystal Biotech's median Finished Goods value was $1.9 million (recorded in 2024), while the average stood at $2.8 million.
  • Examining YoY changes over the last 5 years, Krystal Biotech's Finished Goods showed a top increase of 356335.4% in 2025 and a maximum decrease of 403.18% in 2025.
  • Krystal Biotech's Finished Goods (Quarter) stood at $627000.0 in 2023, then soared by 239.07% to $2.1 million in 2024, then skyrocketed by 242.1% to $7.3 million in 2025.
  • Its Finished Goods was $7.3 million in Q3 2025, compared to $1.7 million in Q2 2025 and $5.9 million in Q1 2025.